These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28502091)

  • 1. Increased Pretransplant Frequency of CD28
    Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
    Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept-Resistant Rejection Is Associated With CD28
    Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
    Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
    Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
    Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
    Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
    Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
    Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
    Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.
    Samy KP; Anderson DJ; Lo DJ; Mulvihill MS; Song M; Farris AB; Parker BS; MacDonald AL; Lu C; Springer TA; Kachlany SC; Reimann KA; How T; Leopardi FV; Franke KS; Williams KD; Collins BH; Kirk AD
    Am J Transplant; 2017 May; 17(5):1193-1203. PubMed ID: 27888551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study.
    Mulvihill MS; Samy KP; Gao QA; Schmitz R; Davis RP; Ezekian B; Leopardi F; Song M; How T; Williams K; Barbas A; Collins B; Kirk AD
    Am J Transplant; 2019 Aug; 19(8):2350-2357. PubMed ID: 30891931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.
    Krummey SM; Cheeseman JA; Conger JA; Jang PS; Mehta AK; Kirk AD; Larsen CP; Ford ML
    Am J Transplant; 2014 Mar; 14(3):607-14. PubMed ID: 24730049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection.
    Espinosa J; Herr F; Tharp G; Bosinger S; Song M; Farris AB; George R; Cheeseman J; Stempora L; Townsend R; Durrbach A; Kirk AD
    Am J Transplant; 2016 Apr; 16(4):1102-12. PubMed ID: 26603381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
    Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
    J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belatacept in kidney transplantation.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection.
    Xu H; Bendersky VA; Brennan TV; Espinosa JR; Kirk AD
    Am J Transplant; 2018 Mar; 18(3):720-730. PubMed ID: 29136317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus-Associated CD4(+) CD28(null) Cells in NKG2D-Dependent Glomerular Endothelial Injury and Kidney Allograft Dysfunction.
    Shabir S; Smith H; Kaul B; Pachnio A; Jham S; Kuravi S; Ball S; Chand S; Moss P; Harper L; Borrows R
    Am J Transplant; 2016 Apr; 16(4):1113-28. PubMed ID: 26603521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells.
    de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Weimar W; Baan CC
    PLoS One; 2016; 11(2):e0148604. PubMed ID: 26919152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.
    Ashokkumar C; Ganguly B; Townsend R; White J; Levy S; Moritz M; Mazariegos G; Sun Q; Sindhi R
    Sci Rep; 2015 Oct; 5():15218. PubMed ID: 26472085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.